The responsible mechanisms involve a gene specific and IKKβ-dependent recruitment of S536 phosphorylated p65 NFκB to IL-8 and CCL2 promoters, suggesting that anti-inflammatory therapy targeting IKKβ might increase the BZ effectiveness in ovarian cancer treatment [41]. Here, CCL2 is linked to ovarian carcinoma.